EE04966B1 - (-)-5-(3-klorofenl)-alfa-(4-klorofenl)-alfa-(1-metl-1H-imidasool-5-l)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks - Google Patents

(-)-5-(3-klorofenl)-alfa-(4-klorofenl)-alfa-(1-metl-1H-imidasool-5-l)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks

Info

Publication number
EE04966B1
EE04966B1 EEP200200695A EEP200200695A EE04966B1 EE 04966 B1 EE04966 B1 EE 04966B1 EE P200200695 A EEP200200695 A EE P200200695A EE P200200695 A EEP200200695 A EE P200200695A EE 04966 B1 EE04966 B1 EE 04966B1
Authority
EE
Estonia
Prior art keywords
chlorophenyl
alpha
preparation
tetrazolo
methanamine
Prior art date
Application number
EEP200200695A
Other languages
English (en)
Estonian (et)
Inventor
Gaston Venet Marc
Ren� Angibaud Patrick
William End David
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE200200695A publication Critical patent/EE200200695A/xx
Publication of EE04966B1 publication Critical patent/EE04966B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP200200695A 2000-06-22 2001-06-13 (-)-5-(3-klorofenl)-alfa-(4-klorofenl)-alfa-(1-metl-1H-imidasool-5-l)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks EE04966B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202181 2000-06-22
PCT/EP2001/006747 WO2001098302A1 (en) 2000-06-22 2001-06-13 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Publications (2)

Publication Number Publication Date
EE200200695A EE200200695A (et) 2004-06-15
EE04966B1 true EE04966B1 (et) 2008-02-15

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200695A EE04966B1 (et) 2000-06-22 2001-06-13 (-)-5-(3-klorofenl)-alfa-(4-klorofenl)-alfa-(1-metl-1H-imidasool-5-l)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks

Country Status (34)

Country Link
US (3) US20030114471A1 (ja)
EP (1) EP1296984B1 (ja)
JP (1) JP4919575B2 (ja)
KR (2) KR100831940B1 (ja)
CN (1) CN1207296C (ja)
AR (1) AR030704A1 (ja)
AT (1) ATE294804T1 (ja)
AU (3) AU2001263962B2 (ja)
BG (1) BG65894B1 (ja)
BR (1) BRPI0111743B8 (ja)
CA (1) CA2410232C (ja)
CZ (1) CZ295278B6 (ja)
DE (1) DE60110592T2 (ja)
EA (1) EA005065B1 (ja)
EE (1) EE04966B1 (ja)
EG (1) EG24180A (ja)
ES (1) ES2241830T3 (ja)
HK (1) HK1058363A1 (ja)
HR (1) HRP20020989B1 (ja)
HU (1) HU229095B1 (ja)
IL (2) IL153560A0 (ja)
IS (1) IS2596B (ja)
JO (1) JO2361B1 (ja)
MX (1) MXPA02012845A (ja)
MY (1) MY127734A (ja)
NO (1) NO324494B1 (ja)
NZ (1) NZ522481A (ja)
PA (1) PA8519501A1 (ja)
PL (1) PL209521B1 (ja)
SA (1) SA01220349B1 (ja)
SK (1) SK285699B6 (ja)
UA (1) UA73572C2 (ja)
WO (1) WO2001098302A1 (ja)
ZA (1) ZA200210305B (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
ATE336496T1 (de) 2002-04-15 2006-09-15 Janssen Pharmaceutica Nv Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
JP2017536403A (ja) * 2014-12-04 2017-12-07 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． デルタ肝炎ウイルス感染の治療
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
PT3640345T (pt) 2015-08-17 2021-12-29 Kura Oncology Inc Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
DK3534885T3 (da) 2016-11-03 2021-04-12 Kura Oncology Inc Farnesyltransferase-inhibitorer til anvendelse i behandling af kræft

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
TR199800825T2 (xx) * 1995-12-08 1998-08-21 Janssen Pharmaceutica N.V. Farnesil protein transferini inhibe eden (imidazol-5-il) metil-2-kinolinon t�revleri.
AU715658B2 (en) 1996-04-03 2000-02-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
CN1094937C (zh) * 1997-04-25 2002-11-27 詹森药业有限公司 具抑制法呢基转化酶作用的喹唑啉酮类
EP0988038B1 (en) 1997-06-02 2002-08-14 Janssen Pharmaceutica N.V. (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
ID27199A (id) 1998-07-06 2001-03-08 Janssen Pharmaceutica Nv Penghambat transferase protein farnesil untuk pengobatan artropatis
IL140721A0 (en) * 1998-07-06 2002-02-10 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
JP3494409B2 (ja) * 1998-08-27 2004-02-09 ファイザー・プロダクツ・インク 抗がん剤として有用なアルキニル置換キノリン−２−オン誘導体
SK2442001A3 (en) * 1998-08-27 2002-10-08 Pfizer Prod Inc Alkynyl-substituted quinolin-2-ones, pharmaceutical compositions, their use in the treatment and method for producing thereof
KR100818541B1 (ko) * 1998-12-23 2008-04-02 얀센 파마슈티카 엔.브이. 1,2-어닐링된 퀴놀린 유도체
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
TR200201297T2 (tr) * 1999-02-11 2002-06-21 Pfizer Products Inc. Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri.
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
EP1267848B1 (en) * 2000-02-24 2007-10-17 Janssen Pharmaceutica N.V. Dosing regimen comprising a farnesyl protein transferase inhibitor for the treatment of cancer
JP4974439B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
AU2002220559A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives

Also Published As

Publication number Publication date
CN1207296C (zh) 2005-06-22
US20030114471A1 (en) 2003-06-19
ES2241830T3 (es) 2005-11-01
CZ295278B6 (cs) 2005-06-15
ZA200210305B (en) 2004-03-19
CA2410232C (en) 2008-10-07
US20070259902A1 (en) 2007-11-08
US8329714B2 (en) 2012-12-11
AU6396201A (en) 2002-01-02
EG24180A (en) 2008-09-28
MY127734A (en) 2006-12-29
AU2006220405A1 (en) 2006-10-12
HUP0300872A3 (en) 2004-11-29
CZ2003114A3 (cs) 2003-05-14
HK1058363A1 (en) 2004-05-14
US20080114009A1 (en) 2008-05-15
EA005065B1 (ru) 2004-10-28
ATE294804T1 (de) 2005-05-15
HU229095B1 (en) 2013-07-29
IS2596B (is) 2010-03-15
IS6590A (is) 2002-10-25
AR030704A1 (es) 2003-09-03
DE60110592T2 (de) 2006-01-19
EA200300048A1 (ru) 2003-04-24
SK285699B6 (sk) 2007-06-07
HRP20020989B1 (en) 2011-05-31
PL209521B1 (pl) 2011-09-30
NZ522481A (en) 2004-09-24
WO2001098302A1 (en) 2001-12-27
BRPI0111743B8 (pt) 2021-05-25
PL358918A1 (en) 2004-08-23
CN1437601A (zh) 2003-08-20
SK502003A3 (en) 2003-05-02
AU2001263962B2 (en) 2006-07-20
NO20026032L (no) 2002-12-16
EP1296984A1 (en) 2003-04-02
HUP0300872A2 (hu) 2003-07-28
SA01220349B1 (ar) 2007-01-23
KR100831940B1 (ko) 2008-05-23
KR20070121847A (ko) 2007-12-27
MXPA02012845A (es) 2003-05-15
NO20026032D0 (no) 2002-12-16
AU2006220405B2 (en) 2009-05-21
BRPI0111743B1 (pt) 2019-03-26
EE200200695A (et) 2004-06-15
BR0111743A (pt) 2003-07-08
CA2410232A1 (en) 2001-12-27
IL153560A (en) 2011-06-30
NO324494B1 (no) 2007-10-29
KR20030009463A (ko) 2003-01-29
IL153560A0 (en) 2003-07-06
JO2361B1 (en) 2006-12-12
KR100846370B1 (ko) 2008-07-15
EP1296984B1 (en) 2005-05-04
DE60110592D1 (de) 2005-06-09
JP2004501153A (ja) 2004-01-15
BG107310A (bg) 2003-07-31
HRP20020989A2 (en) 2005-02-28
BG65894B1 (bg) 2010-04-30
PA8519501A1 (es) 2002-08-29
UA73572C2 (en) 2005-08-15
JP4919575B2 (ja) 2012-04-18
US8318753B2 (en) 2012-11-27

Similar Documents

Publication Publication Date Title
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
GEP20053511B (en) ) β-Carboline Derivatives Useful as Inhibitors of Phosphodiesterase
TW200505924A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
IL182893A0 (en) PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
DE60118547D1 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
AR048324A1 (es) Metodos para tratar infecciones por vih
JP2005537234A5 (ja)
CA2416492A1 (en) Treatment of glycogen storage disease type ii
MY139072A (en) Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
EE04966B1 (et) (-)-5-(3-klorofenl)-alfa-(4-klorofenl)-alfa-(1-metl-1H-imidasool-5-l)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks
AU2972701A (en) 3-aminopyrazole inhibitors of cyclin dependent kinases
WO2002102743A3 (de) Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
MXPA05012826A (es) Compuestos utiles en la terapia de la enfermedad de alzheimer y formulaciones que los contienen.
YU25202A (sh) Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera
JO2296B1 (en) Substituted pyrolates
ATE308995T1 (de) Pharmazeutische zusammensetzung und verfahren zur behandlung von retroviralen infektionen
WO2003066806A3 (en) Therapeutic use of aziridino compounds
JO2360B1 (en) Substituted pyrolates
UA36468A (uk) Спосіб зняття потягу до алкоголю гомеопатичним засобом "неовітал плюс"

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231